-
1 Comment
Xero Limited is currently in a long term uptrend where the price is trading 5.7% above its 200 day moving average.
From a valuation standpoint, the stock is 65.1% cheaper than other stocks from the Technology sector with a price to sales ratio of 24.9.
Xero Limited's total revenue rose by 21.0% to $410M since the same quarter in the previous year.
Its net income has increased by 2481.3% to $34M since the same quarter in the previous year.
Finally, its free cash flow grew by 1081.3% to $61M since the same quarter in the previous year.
Based on the above factors, Xero Limited gets an overall score of 5/5.
ISIN | NZXROE0001S2 |
---|---|
Exchange | AU |
CurrencyCode | AUD |
Sector | Technology |
Industry | Software - Application |
PE Ratio | 140.8 |
---|---|
Target Price | 199.9887 |
Market Cap | 29B |
Beta | 1.0 |
Dividend Yield | None |
Xero Limited, together with its subsidiaries, engages in the provision of online business solutions for small businesses and their advisors in Australia, New Zealand, the United Kingdom, North America, and internationally. It offers accounting, payroll, payments and other solutions through its Xero platform. The company also provides Planday, an online employee scheduling software; Hubdoc for bills and receipts; Syft, which creates reports, forecasts, dashboards, and consolidations with AI insights; TaxCycle, a tax preparation software for accountants and bookkeepers; and Tickstar, an e-invoicing product. Xero Limited was incorporated in 2006 and is headquartered in Wellington, New Zealand.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for XRO.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025